Centro Gutman

Centro Gutman, ubicado en Palermo (CABA, Argentina), se especializa en oncología. Con 4 años de trayectoria, realiza estudios clínicos Fase II-IV. Cuenta con laboratorio, hospital de día y un equipo multidisciplinario. Enfocado en la atención diaria del paciente, impulsa investigación clínica de calidad con recursos innovadores y colaboración multi sponsor.

Centro Gutman

Av. Sta. Fe 3233, C1425BGH Cdad. Autónoma de Buenos Aires, Argentina

Websitehttps://icm.center

Select an option

I am a doctor

I am a sponsor

Patients Benefits

Sistema de traslado centralizado

Sistema de reembolso a participantes sin latencia

Hotelería en proximidad para pacientes del interior

Our team

Medical staff

Marcela De Souza

Mariano Dioca

María Inés Bianconi

Nicolás Torressi

Fernando Galanternik

Open studies

Lung cancer

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. - eVOLVE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZeneca

Breast Cancer

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and Company

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - TROPION-Breast05 - AstraZeneca

Fatty liver/nash

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.

Steatohepatitis

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.

Bladder Cancer

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer - MoonRISe-1 - Janssen Research & Development, LLC

Cirrhosis

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

Colorectal cancer

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation - CodeBreaK 301 - Amgen

Urothelial cancer

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

Centro Gutman

Av. Sta. Fe 3233, C1425BGH Cdad. Autónoma de Buenos Aires, Argentina

Websitehttps://icm.center

Select an option

I am a doctor

I am a sponsor

Patients Benefits

Sistema de traslado centralizado

Sistema de reembolso a participantes sin latencia

Hotelería en proximidad para pacientes del interior

Our team

Medical staff

Marcela De Souza

Mariano Dioca

María Inés Bianconi

Nicolás Torressi

Fernando Galanternik

Open studies

Lung cancer

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. - eVOLVE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) - ARTEMIDE-Lung02 - AstraZeneca

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC - ARTEMIDE-Lung03 - AstraZeneca

Breast Cancer

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer - EMBER-4 - Eli Lilly and Company

Fatty liver/nash

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.

Steatohepatitis

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) - ENLIGHTEN-Fibrosis - 89bio, Inc.

Bladder Cancer

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer - MoonRISe-1 - Janssen Research & Development, LLC

Cirrhosis

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH - ENLIGHTEN-Cirrhosis - 89bio, Inc.

Colorectal cancer

Urothelial cancer

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads